cbdMD Inc. (YCBD) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, cbdMD Inc. (NYSE: YCBD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $0.39 (+4.56% 1D, market cap $4.3M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 5/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.
Within the Consumer Discretionary sector (Package Goods/Cosmetics), YCBD carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of 62.4%, and ROIC of -30.4%. By comparison, BYAH (Park Ha Biological Technology Co. Ltd. (Class A)) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $7.9M) and BNKK (Bonk Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $9.4M). Among the 5-stock peer group, UG leads on earnings multiple (14.5x) while UG leads on capital efficiency (17.8% ROIC).
Per YCBD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001644903), cbdMD Inc. generated $19.2M in revenue (-1.5% YoY), -$2.0M in net income, and -$1.6M in free cash flow against $11.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Consumer Discretionary with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While YCBD currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Consumer Discretionary with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.44) and Max Pain ($0.41) forces dealer call-delta covering toward $2.69.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
cbdMD Inc. (YCBD) surged +4.56% to $0.39, trading at 3% of its 52-week range ($0.33 – $2.56). Stretched risk/reward at current multiples (-30% return on capital) under elevated 10-year interest-rate pressure.
Gainers Lakewood-Amedex (NASDAQ:LABT) stock rose 20.4% to $0.34 during Wednesday's after-market session. Glaukos (NYSE:GKOS) stock rose 16.85% to $212.01. The company's market cap stands at $10.6 billion. As
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -1.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on YCBD today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for YCBD. Explore sector supply chains on /butterfly.
Across 1011 tracked Consumer Discretionary securities in the Roarable RQD universe, cbdMD Inc. (YCBD) ranks #795 by composite RQD confidence (37/100, grade D-) and #973 by equity capitalization ($4.3M). Within this direct 5-issuer industry benchmark cohort, UG leads on earnings valuation at 14.5x trailing P/E, while UG leads on capital efficiency and profitability with 17.8% ROIC and — gross margin. UG currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with YCBD at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| YCBD
ACTIVE
cbdMD Inc. | D- | 37/100 | — | 62.4% | -30.4% | +4.56% | $4.3M | Benchmark Subject |
| BYAH Park Ha Biological Technology Co. Ltd. (Class A) | D | 45/100 | — | 94.4% | — | +1.71% | $7.9M | /byah-vs-ycbd → |
| BNKK Bonk Inc. | D- | 35/100 | — | 58.5% | -35.0% | -2.48% | $9.4M | /bnkk-vs-ycbd → |
| CABR Caring Brands Inc. | D- | 37/100 | — | 55.6% | -35.0% | -4.46% | $11.2M | /cabr-vs-ycbd → |
| UG United-Guardian Inc. | C- | 61/100 | 14.5x | — | 17.8% | -1.19% | $30.6M | /ug-vs-ycbd → |
In its most recent audited fiscal period (FY2025, filed 2025-09-30), cbdMD Inc. (YCBD) reported GAAP revenue of $19.2M (-1.5% vs. FY2024 revenue of $19.5M , and -20.6% cumulative change since FY2023) , GAAP net income of -$2.0M, operating cash flow of -$1.5M, and free cash flow of -$1.6M (-201.5% YoY). On the balance sheet, YCBD closed FY2025 with $11.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-09-30 | $19.2M | -$2.0M | -$1.5M | -$1.6M | $11.8M | — |
| FY2024 (FY) | 2024-09-30 | $19.5M | -$3.7M | -$352.8K | -$542.8K | $11.5M | — |
| FY2023 (FY) | 2023-09-30 | $24.2M | -$22.9M | -$4.3M | -$4.3M | — | — |
As of 2026-11-02, cbdMD Inc. (NYSE: YCBD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $0.39 (+4.56% 1D, market cap $4.3M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 5/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.
Within the Consumer Discretionary sector (Package Goods/Cosmetics), YCBD carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of 62.4%, and ROIC of -30.4%. By comparison, BYAH (Park Ha Biological Technology Co. Ltd. (Class A)) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $7.9M) and BNKK (Bonk Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $9.4M). Among the 5-stock peer group, UG leads on earnings multiple (14.5x) while UG leads on capital efficiency (17.8% ROIC).
Per YCBD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001644903), cbdMD Inc. generated $19.2M in revenue (-1.5% YoY), -$2.0M in net income, and -$1.6M in free cash flow against $11.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Consumer Discretionary with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
YCBD last traded at $0.39 (+4.56% on volume of 161,240 shares), positioning the stock -11.36% below its 50-day simple moving average ($0.44) and -40.91% below its 200-day simple moving average ($0.66). Across its 52-week range of $0.33 to $2.56, YCBD sits at the 2.7% percentile with a 14-day RSI of 47.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.44).
Why YCBD Stock surged +4.56% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-30% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).